Výsledky vyhledávání

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis

Autor: J J, Cook, S J, Gardell, M A, Holahan, G R, Sitko, G L, Stump, A A, Wallace, D B, Gilberto, T R, Hare, J A, Krueger, D L, Dyer, P E, Sanderson, J P, Vacca, J A, Shafer, J J, Lynch

Publikováno v: The Journal of pharmacology and experimental therapeutics. 289(1)

The small molecule direct thrombin inhibitor L-374,087 was characterized across species in an in vitro activated partial thromboplastin clotting time (aPTT) assay and in vivo in rhesus monkey and dog thrombosis models. In vitro in rhesus, dog, and hu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::18021a3235890db95baa6d91177f5761
https://pubmed.ncbi.nlm.nih.gov/10087043

Zobrazit plný text záznamu

Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury

Autor: J J, Cook, J D, Glass, G R, Sitko, M A, Holahan, R F, Stupienski, A A, Wallace, G L, Stump, E L, Hand, B C, Askew, G D, Hartman, R J, Gould, J J, Lynch

Publikováno v: Circulation. 96(3)

A conscious dog model of left circumflex coronary artery electrolytic injury was used to assess the oral antithrombotic efficacy of L-738,167, a potent nonpeptide antagonist of platelet GP IIb/IIIa. L-738,167 was administered either as a single oral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::987ed74e23104b5e16148c5ae87e489f
https://pubmed.ncbi.nlm.nih.gov/9264506

Zobrazit plný text záznamu

Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction

Autor: J J, Lynch, A A, Wallace, G L, Stump, R F, Stupienski, T, Kothstein, J R, Gehret

Publikováno v: The Journal of pharmacology and experimental therapeutics. 277(2)

Class III activity has been proposed as a potential mechanism for the treatment of reentrant arrhythmias. The purpose of the present study was to assess the concordance in antiarrhythmic efficacy of MK-499, a selective blocker of IKr, the rapidly act

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b08f707a42e01003e66bae21382f02c3
https://pubmed.ncbi.nlm.nih.gov/8627544

Zobrazit plný text záznamu

Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs

Autor: B P, Damiano, E C, Giardino, B J, Haertlein, G L, Stump, J A, Mitchell, R, Falotico

Publikováno v: Journal of cardiovascular pharmacology. 23(2)

RWJ-29009, (6S)-trans(-)-1-(6,7-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-5 H-thieno[3,2-b]pyran-7-yl)-2-piperidinone, is a structurally novel and extremely potent potassium channel activator that may be useful for treatment of hypertension and ischemic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8d29535aa42e0174c9f4269af94f5f63
https://pubmed.ncbi.nlm.nih.gov/7511761

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání